Overview

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
Phase:
Phase 2
Details
Lead Sponsor:
Tarsa Therapeutics, Inc.
Treatments:
Calcitonin
Calcitonin Gene-Related Peptide
Katacalcin
Salmon calcitonin